1-10 of 10
Yinzhi Lai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial

Free
Valeria Santini, Matteo Della Porta, Rami Komrokji, Veronika Pozharskaya, Thalia Farazi, Karen Keeperman, Yinzhi Lai, Dimana Miteva, Tracy Krimmel, Barkha Aggarwal, David Valcarcel, Pierre Fenaux, Jake Shortt, Uwe Platzbecker, Guillermo Garcia-Manero, Amer Zeidan
Journal: Blood
Blood (2025) 146 (Supplement 1): 792.
https://doi.org/10.1182/blood-2025-792
Published: 2025
Journal Articles

Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilus

Free
Amer Zeidan, Maria Diez-Campelo, Valeria Santini, Rena Buckstein, Lionel Adès, Lea Sahagun, Gitanjali Das, Tatiana Zelinsky, Yinzhi Lai, Dimana Miteva, Ali McBride, Jose Alberto Nadal, Krzysztof Madry, David Valcarcel, Jose Miguel Torregrosa Diaz, Dries Deeren, Sebastian Grosicki, Sangeetha Venugopal, Uwe Platzbecker, Matteo Della Porta
Journal: Blood
Blood (2025) 146 (Supplement 1): 789.
https://doi.org/10.1182/blood-2025-789
Published: 2025
Journal Articles

Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial

Free
Valeria Santini, Amer M. Zeidan, Uwe Platzbecker, Rami S. Komrokji, Guillermo Garcia-Manero, Dimana Miteva, Aylin Yucel, Veronika Pozharskaya, Shelonitda Rose, Yinzhi Lai, Ana Carolina Giuseppi, David Valcárcel Ferreiras, Pierre Fenaux, Jake Shortt, Matteo Giovanni Della Porta
Journal: Blood
Blood (2024) 144 (Supplement 1): 1818.
https://doi.org/10.1182/blood-2024-194239
Published: 2024
Journal Articles

Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial

Free
Guillermo Garcia-Manero, Matteo Giovanni Della Porta, Valeria Santini, Amer M. Zeidan, Rami S. Komrokji, Pierre Fenaux, David Valcárcel, Jake Shortt, Mrudula B. Glassberg, Aylin Yucel, Yinzhi Lai, Dimana Miteva, Shelonitda Rose, Ahmed Hnoosh, Uwe Platzbecker
Journal: Blood
Blood (2024) 144 (Supplement 1): 1832.
https://doi.org/10.1182/blood-2024-198304
Published: 2024
Journal Articles

Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent-Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial

Free
Guillermo Garcia-Manero, Valeria Santini, Amer M. Zeidan, Rami S. Komrokji, Veronika Pozharskaya, Karen L. Keeperman, Yinzhi Lai, Barkha Aggarwal, Dimana Miteva, David Valcárcel Ferreiras, Pierre Fenaux, Jake Shortt, Matteo Giovanni Della Porta, Uwe Platzbecker
Journal: Blood
Blood (2024) 144 (Supplement 1): 350.
https://doi.org/10.1182/blood-2024-194240
Published: 2024
Journal Articles

Clinical Parameters, Anemia, and Spleen Response in Patients with MF-Related Anemia Treated with Luspatercept: Efficacy Sub-Analysis from the ACE-536-MF-001 Study

Free
Aaron T. Gerds, Claire N Harrison, Jean-Jacques Kiladjian, Ruben Mesa, Rami S. Komrokji, Prithviraj Bose, Fabian Sanabria, Niloufar Marsousi, Yinzhi Lai, Francesco Passamonti
Journal: Blood
Blood (2023) 142 (Supplement 1): 4565.
https://doi.org/10.1182/blood-2023-178536
Published: 2023
Journal Articles

Efficacy and Safety of Luspatercept in Patients with HbE/β-Thalassemia from the BELIEVE Study: A Subgroup Analysis

Free
Kevin H.M. Kuo, Pranee Sutcharitchan, Ping Chong Bee, Lee Ping Chew, Soo Min Lim, Ai Sim Goh, Sadanand Vodala, Wen-Ling Kuo, Yinzhi Lai, Loyse Felber Medlin, Martina Perin, Luciana Moro Bueno, Thomas D Coates, Vip Viprakasit
Journal: Blood
Blood (2023) 142 (Supplement 1): 3848.
https://doi.org/10.1182/blood-2023-174082
Published: 2023
Journal Articles

Long-Term Evaluation of Luspatercept in Erythropoiesis-Stimulating Agent (ESA)-Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study

Free
Valeria Santini, Rami S. Komrokji, Guillermo Garcia-Manero, Rena Buckstein, Esther Natalie Oliva, Karen L. Keeperman, Shelonitda Rose, Ana Carolina Giuseppi, Valerie Vilmont, Yinzhi Lai, Dimana Miteva, Barkha Aggarwal, Uwe Platzbecker, Pierre Fenaux, Amer M. Zeidan
Journal: Blood
Blood (2023) 142 (Supplement 1): 915.
https://doi.org/10.1182/blood-2023-178546
Published: 2023
Journal Articles

Efficacy and Safety of Luspatercept in Patients Enrolled in the BELIEVE Trial: Data from the Phase 3b Long-Term Rollover Study

Free
Maria Domenica Cappellini, Ali T Taher, Vip Viprakasit, Pencho Georgiev, Kevin H.M. Kuo, Natalia Holot, Valérie Vilmont, Loyse Felber Medlin, Wen-Ling Kuo, Yinzhi Lai, Luciana Moro Bueno, Sujit Sheth
Journal: Blood
Blood (2023) 142 (Supplement 1): 3849.
https://doi.org/10.1182/blood-2023-174089
Published: 2023
Journal Articles

Survival Outcomes for Patients in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine or Placebo

Free
Farhad Ravandi, Pau Montesinos, Michael Pfeilstöcker, Cristina Papayannidis, Hervé Dombret, Yinzhi Lai, Erica Petrlik, Thomas Prebet, Hartmut Döhner
Journal: Blood
Blood (2022) 140 (Supplement 1): 3277–3279.
https://doi.org/10.1182/blood-2022-159045
Published: 2022